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Background: Hematopoietic prostaglandin D2 synthase (H-PGDS, GST Sigma) is a member of the glutathione
S-transferase super family of enzymes that catalyses the conjugation of electrophilic substances with reduced
glutathione. The enzyme catalyses the conversion of PGH2 to PGD2 which mediates inflammatory responses. The
inhibition of H-PGDS is of importance in alleviating damage to tissues due to unwarranted synthesis of PGD2.
Combretum molle has been used in African ethno medicinal practices and has been shown to reduce fever and
pain. The effect of C. molle alkaloid extract on H-PGDS was thus, investigated.
Methods: H-PGDS was expressed in Escherichia coli XL1-Blue cells and purified using nickel immobilized metal
affinity chromatography. The effect of C. molle alkaloid extract on H-PGDS activity was determined with 1-chloro-2,
4-dinitrobenzene (CDNB) as substrate. The effect of C. molle alkaloid extract with time on H-PGDS was determined.
The mechanism of inhibition was then investigated using CDNB and glutathione (GSH) as substrates.
Results: A specific activity of 24 μmol/mg/min was obtained after H-PGDS had been purified. The alkaloid extract
exhibited a 70% inhibition on H-PGDS with an IC50 of 13.7 μg/ml. C. molle alkaloid extract showed an uncompetitive
inhibition of H-PGDS with Ki = 41 μg/ml towards GSH, and non-competitive inhibition towards CDNB with
Ki = 7.7 μg/ml and Ki′ = 9.2 μg/ml.
Conclusion: The data shows that C. molle alkaloid extract is a potent inhibitor of H-PGDS. This study thus supports
the traditional use of the plant for inflammation.
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The inflammatory process may be defined as a sequence
of events that occurs in response to noxious stimuli, an
infection or trauma [1]. It is the first response of the im-
mune system to infection or irritation and is a protective
attempt by the organism to remove injurious stimuli and
initiate the healing process [2]. Inflammation is a self-
defense reaction in its first phase and, hence, is regarded
as the main therapeutic target and the best choice to
treat the disease and alleviate symptoms [3]. Inflamma-
tion plays an important role in various diseases, such as* Correspondence: smukanganyama01@gmail.com
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unless otherwise stated.rheumatoid arthritis, atherosclerosis and asthma, which
all show a high prevalence globally [4].
The inflammatory process is mediated by prostaglandins
which are synthesized from arachidonic acid. Prostaglandin
D2 is an acidic lipid mediator which is responsible for the
regulation of body temperature, hormone release, olfactory
reaction, sleep, prevention of platelet aggregation and pain
responses [5]. PGD2 interacts with two types of G protein
coupled receptors that is DP1 and DP2. The DP2 receptors
are also known as chemo-attractant receptor homologous
on T helper 2 cells (CRTH2) [2]. DP1 receptors are found
on murine and dendritic cells and DP2 on Th2, eosinophils
and basophils. DP2 receptors mediate eosinophil chemo-
taxis and are involved in Th2 related inflammation [2].
PGD2 is formed by the action of two types of prostaglandin
D2 synthase isoforms that is lipocalin and hematopoietictd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the central nervous system, testis and human heart.
Production of PGD2 is mainly mediated by a glutathione-
dependent hematopoietic prostaglandin D2 synthase
(H-PGDS) [6]. Hematopoietic prostaglandin D2 synthase
(H-PGDS) is widely distributed in antigen-presenting cells,
T helper (Th2) lymphocytes, mast cells, and megakaryo-
cytes, where it selectively metabolizes cyclooxygenase-
derived PGH2 to PGD2 [7]. H-PGDS is characterised as a
member of the Sigma class of GST gene family which ca-
talyses the conjugation of glutathione (GSH) to an electro-
philic substrate [8]. The high specificity of the enzyme for
the production of PGD2 is attributed to the unique struc-
ture of the catalytic unit which is deep and wide unlike
the catalytic units for other GSTs which are narrow and
shallow [5]. Inhibition of H-PGDS has been shown to be
very protective in mouse models with allergic airway in-
flammation [9]. Thus, by analogy H-PGDS appears to be a
promising target for the design of anti-allergic and anti-
inflammatory drugs.
Non - steroidal anti - inflammatory drugs (NSAIDs) are
among the most commonly used drugs worldwide to aid
in treating inflammatory conditions. It is estimated that
up to 60% of individuals taking NSAIDs will experience
side effects and also some of the NSAIDs such as na-
proxen have been shown to contribute to a 50% higher
risk of heart attack and stroke with long term use [10].
Due to these side effects alternative forms of medicine
may help in managing inflammatory conditions.
Ethnobotanical knowledge on plants possessing anti-
inflammatory and analgesic properties can open up to
new drugs in inflammatory disorders [11]. Medicinal
plants constitute an effective source of medicines and
herbal medicines have been shown to have profound
utility with about 80% of rural population depending on
it for their primary health care [12]. In Zimbabwe the
leaves of Rhus dentate, Ochna pulchra have been used to
treat stomach pains. Chimbwidi and Dalbergia melsnoxylon
have also been used to treat asthma [13].
Ojewole [14], found analgesic, anti-inflammatory and
cardiovascular effects of mollic acid glucoside isolated
from C. molle leaves and antiprotozoal activity from the
acetone extract of leaves from the same plant. C. molle
was found to have anti-asthmatic and anti-tussive activ-
ities [15]. In an investigation of the biological activity of
different Combretum species, C. molle was found to have
both anti-inflammatory and anti-schistosomal activity
[16]. Inflammatory diseases are a major and worldwide
problem [17]. An important mediator of inflammation is
PGD2 which is produced from PGH2 by H-PGDS. Very
few studies have been done on H-PGDS, which is an en-
zyme that has been linked to the inflammation process.
Of the few studies done it was shown that H-PGDS is
associated with inflammation and allergic reactions [5,9].According to other studies on Combretum species, al-
kaloids have been shown to have anti-inflammatory
properties [18]. The effects of un-fractionated alkaloids
from C. molle were, thus, determined in this study. The
main objective of this study was to investigate the effects
of alkaloids isolated from C. molle on H-PGDS.
Methods
Chemicals
Human recombinant H-PGDS was a kind gift from
Professor Bengt Mannervik (Uppsala, Sweden). Ethacrynic
acid, cibacron blue, CDNB, GSH were products of Sigma
Aldrich. All chemicals unless stated otherwise were
purchased from Sigma-Aldrich (Steinheim, Germany).
Plant collection and preparation
The leaves of C. molle were collected from Centenary in
Mashonaland Central Province of Zimbabwe. The plant
was authenticated and classified by Mr. Christopher
Chapano, a taxonomist at the National Herbarium and
Botanic Gardens (Harare, Zimbabwe). Herbarium plant
samples were kept at the Department of Biochemistry,
University of Zimbabwe, Harare, Zimbabwe. Leaves of
Combretum molle were separated from the plant and
then dried at an ambient temperature of 50°C in an
oven (Memmert, SRG, SchwaBach, , Germany). The dried
leaves were ground to a powder using a two speed blender
(BL2, ABB, Moulinex, France) so as to optimize the solv-
ent contact during the extraction process. The powders
were weighed on a digital balance (Kern EG, Balingen,
Germany) and their masses were recorded.
Extraction
The leaf powder was extracted with ethanol and acetone.
An aliquot of 5 g of the powdered sample was weighed
on a balance (Kern and Sohn Co., Balingen, Germany)
and mixed with 25 ml ammonia and 50 ml 10% ethanol.
The mixture was mixed thoroughly on Vortex mixer
(Thermolyne Maxi Mix II, IOWA, USA) and placed in a
water bath at 40°C for 10 minutes. The mixture was
then filtered through a Whatman filter paper 1 and air
dried under a fan. The powder obtained was packed in
50 ml test tubes and stored at 25°C for future use.
Expression and purification of H-PGDS
H-PGDS was expressed from a pJexpress 401plasmid in
E.coli XL1-blue cells. The gene also coded for hexahisti-
dine tail. Luria Bertani (LB) medium was prepared and
kanamycin was added to a final concentration of 50 μg/ml.
A volume of 5 ml of the incubated H-PGDS containing
E. coli cells was added to each of 2 flasks each containing
500 ml media. The expression of H-PGDS was induced by
the addition of isopropyl-beta-thiogalactopyranoside (IPTG)
after the absorbance (OD) of 0.4, at λ= 600nm was reached
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0.2 mM. The cells were then incubated at 160 rpm at
37°C for a further 15 hours in a SI 300 Lab companion,
(Jeio Tech, Seoul, Korea). A pellet was obtained after
centrifugation at 3 000 rpm for 5 minutes using a Het-
tich Rotofix 32 A centrifuge (Tuttlingen, Germany). The
pellet obtained from centrifuging was lysed with a lysis
buffer (pH 8 phosphate buffer 50 mM, 0.3 M sodium
chloride, 10 mM imidazole, 1 mg/ml lysozyme).
This mixture was sonicated using a sonicator (Vibra cell,
New York, USA) 2 × 20 s treatment stopping at 2 minutes
interval to avoid damaging the protein by heating. Phenyl-
methylsulfonyl fluoride (PMSF) was added to a final con-
centration of 170 μM to inhibit proteases. This mixture
was then centrifuged using a Beckman Optima LE-80 K
ultracentrifuge, (Beckman instruments, California, USA)
at 105 000 × g for 1 hour. The supernatant was retained
while the pellet was discarded. Protein was then purified
by nickel immobilized metal affinity chromatography
using Ni Cam affinity resin following the manufacturer’s
instructions Sigma-Aldrich (Steinheim, Germany). The
fractions collected from the column were tested for H-
PGDS activity using CDNB as a substrate. The fractions
that exhibited activity were pooled and concentrated
using an IVSS Vivapore 10 /20 concentrator (VP2001
Satorius Stedim Biotech, Stonehouse, UK) with a molecu-
lar weight cut off of 7500 daltons. The concentrated solu-
tion was then dialyzed against 2 × 5 L of dialysis buffer
(50 mM sodium phosphate pH 8, 1 mM EDTA, 0.2 mM
DTT, 0.02% NaN3) using a membrane with a molecular
cut off of 12 000 daltons.
The purity of the enzyme purification fractions was
determined by sodium dodecyl sulphate polyacrylamide
gel electrophoresis (SDS-PAGE), carried out on 15% slab
gels using a Hoeffer SE Mighty Small II electrophoresis
system (Hoeffer Scientific Instruments, California, USA).
Protein bands were stained with Coomasie Blue-G.Screening for Inhibition of H-PGDS by alkaloids from
C. molle
The effect of C. molle alkaloid extract on H-PGDS was
tested at 300 μg/ml. The enzyme activity was determined
through the measurement of the conjugation activity
with CDNB at 340 nm using SQ Single Beam Scanning
UV/Visible Spectrophotometer (United Products and in-
struments Inc., USA) and was done in quadruplicate.
For the determination of IC50, a 2 fold serial dilution of
C. molle extracts were carried out from 0 to 300 μg/ml
in a 96 well plate. The assay with CDNB was adapted for
measurement of absorbance with a SpectraMax Plus
microplate spectrophotometer equipped with a kinetics
mode (Molecular Devices, Sunnyvale, California, USA) at
380 nm using an extinction coefficient of 7.825 μM−1 cm−1.Determination of time-dependent effects
The incubation mixtures contained H-PGDS (final con-
centration 0.0625 μM), 0.2 M potassium phosphate buffer
pH 7.4 with 0.2 mM EDTA, and (15, 30, 60 μg/ml) C.
molle alkaloid extract. The incubations were carried out at
a temperature of 30°C. The experiment was carried out at
timed intervals from 0–1 hour, beginning with incubation
for the 1 hour sample and lastly with the 0 hour time sam-
ple. Immediately, 20 μl of each sample was withdrawn and
assayed for GST activity. These incubations were run in
parallel with positive and negative controls. The negative
control contained H-PGDS and buffer. Cibacron blue was
used as the positive control.
Determination of kinetic constants for H-PGDS using
CDNB and GSH as substrates
The effects of alkaloids from C. molle on the kinetics of
H-PGDS were determined as described previously [19].
Activity with CDNB was measured by determining the
absorbance with a SpectraMax Plus microplate spectro-
photometer equipped with a kinetics mode (Molecular
Devices, Sunnyvale, CA, USA). The Km(app) and Vmax(app)
were determined using GraphPad Prism™ version 5.00.
The Ki values with respect to GSH and CDNB, as well as
the type of inhibition were determined. The type of inhib-
ition was deduced by determination of trends of Km and
Vmax values with increase in natural product concen-
tration. To determine the trend, the means of the Km
(or Vmax) values with increase in inhibitor concentration
were compared by performing a one-way ANOVA with
Dunnett’s post test using Graph Pad 5.00 (Graph Pad Prism
Inc. San Diego, CA, USA). The inhibition constant, Ki, was
determined by means of re-plots [19]. The type of re-plot
depends on the type of inhibition, for example, plotting
1/Vmax versus inhibitor concentration for non-competitive
inhibition will give Ki as the intercept on the baseline.
Statistical analysis
Data analyses were performed using GraphPad Instat
software® (GraphPad Prism Inc. San Diego, CA, USA).
Levels of significance were determined using ANOVA
using the Dunnett post test were all columns of treat-
ments were compared to the control. All data were
expressed as mean ± standard deviation. P ≤ 0.05 values
or less were considered to indicate statistically signifi-
cant difference).
Results
Coomassie blue staining and Western blot for poly-His tag
H-PGDS was expressed in E. coli and was purified by
Nickel affinity chromatography. The H-PGDS was purified
to homogeneity and a single band was obtained on SDS-
PAGE analyses. The molecular weight of the protein was
23.4 kDa and the specific activity was 24 units/mg.
Figure 2 The time-dependent effects of the alkaloids on GST
Sigma over 60 minutes at concentrations 15, 30 and 60 μg/ml of
plant extract. The incubations of the enzyme and the plant extract
were carried out at a temperature of 30°C for a period of 0–1 hour.
Samples of 20 μl of each sample were withdrawn at timed intervals
and assayed for GST activity. The H-PGDS was not inactivated, however,
there was a dose-dependent decrease in enzyme activity with time.
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The effects of the alkaloids from C. molle on the activity
of H-PGDS activity were assessed using the CDNB assay
for GSTs. Inhibition activity of the extract at 300 μg/ml
plant concentration was determined as the percentage
remaining activity of the enzyme in the presence of the
plant extract. The percentage inhibition obtained was
70%. The IC50 for the alkaloids was determined spectro-
photometrically using CDNB as the substrate. Figure 1
shows the sigmoidal dose response curve for the deter-
mination of the IC50 for the alkaloids which was found
to be 13.7 μg/ml.
Time-dependent effects of alkaloids on H-PGDS
To assess if the alkaloid extract could inactivate H-PGDS,
the time-dependent effects of the enzyme by C. molle al-
kaloid extract were carried out over an hour and the
values obtained were analyzed and presented graphically
as % remaining activity against time as shown in Figure 2.
The figure shows results for the effects of 15 μg/ml plant
extract (low concentration), 30 μg/ml plant extract
(middle concentration) and 60 μg/ml plant extract (high
concentration). The results show that the effects of the al-
kaloids were direct, concentration-dependent and did not
depend on time. Cibacron blue was used as the positive
control.
The effects of the alkaloids on H-PGDS kinetics
Based on the results for the inhibitory effects of alkaloids,
their kinetics with H-PGDS were determined. The trend
in changes of Km
GSH/CDNB and Vmax
GSH/CDNB values with in-
crease in alkaloid concentration was used to determineFigure 1 The inhibitory effect of C. molle on GST Sigma with
increasing concentration of plant extract. The concentration of
natural product required to bring about 50% inhibition of GST
activity, the IC50 value, was determined by plotting sigmoidal dose
response curves of percent enzyme activity vs. log natural product
concentration using GraphPad Prism version 5.00 (GraphPad™ Software
Inc., San Diego, California, USA). The IC50 value determined from the
graph was 13.7 μg/ml.the type of inhibition [20]. The predominant type of inhi-
bitions with respect to the G site (GSH) was uncompeti-
tive and with the H site (CDNB) was non-competitive.
Figures 3 and 4 shows the Michaelis-Menten and
Lineweaver-Burk plots with GSH and CDNB as these sub-
strates were varied respectively. Figures 5 and 6 shows the
secondary plots for determination of Ki and Ki′ values
for the alkaloids with GSH and CDNB respectively on
H-PGDS. The data for the effects of the alkaloids on
H-PGDS kinetics was summarised in Table 1. It was
shown that the Kcat/Km for GSH was increased with an
increase in the inhibitor concentration and that the
Kcat for both substrates decreased with an increase in
inhibitor concentration.
Discussion
Inflammation is a major worldwide health burden in
both developing and developed countries [17]. Chronic
inflammation can lead to various conditions such as can-
cer, asthma, rheumatoid arthritis, atherosclerosis, peri-
odontitis, and hay fever [3]. The search for safe and
efficacious agents for use in inflammatory conditions is
ongoing with the objective to find new drugs which are
efficacious but with few side effects. Conventional medi-
cines have been shown to possess many side effects and,
thus, effort is being put into research or new drugs [21]. An
important prostaglandin involved in inflammation is PGD2
which is produced by H-PGDS. H-PGDS negative mice
generated by standard gene targeting technology showed
diminished symptoms of disease indicating diminished
inflammatory reaction in the absence of H-PGDS [22].
A considerable number of studies have suggested that
extracts or active principles obtained from Combretum
Figure 3 Inhibition profile of C. molle alkaloids on H-PGDS. A shows the Michaelis-Menten plot and B the Lineweaver-Burk plot of GST Sigma.
In the assay H-PGDS activity was measured with varying concentrations of GSH and different inhibitor concentrations; 0, 2, 5, 10 and 20 μg/ml
whilst CDNB concentration was fixed at 1.5 mM.
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cluding antibacterial, antiprotozoal, anticancer, cytotoxic,
analgesic, anti-inflammatory, hepatoprotective and anti-
viral activities [23]. C. molle is used in traditional medical
practices in Zimbabwe to treat pain and inflammation
[24]. The aim of the present study was to collect informa-
tion on the possible pharmacological and molecular basis
for the efficacy of the plant alkaloids on the effective man-
agement of inflammation. The preliminary studies in our
research group showed that the crude plant leaf extract of
C. molle brought about 87% inhibition of the H-PGDS.
An alkaloid extract from C. molle was then assayed for its
activity against H-PGDS.
Alkaloids are abundant in the leaves of C. molle and
have been reported to have significant pharmacological
activities. Previous studies on this plant led to the isolation
of triterpenoids glycosides, tannins, alkaloids, saponins,
stilbenes, triterpene saponin oleanone trypetitepene, arju-
nolic acid and mollic acid glucosides which demonstrated
cytotoxic, antifungal, antimicrobial and anti-inflammatory
activity [25]. According to the histochemical studies
done in a previous study [26], the main constituents ofC. molle leaves were found to be phenolics, flavonoids
and alkaloids.
Analgesic and anti-inflammatory properties of mollic acid
glucoside (MAG), an alkaloid, a 1α-hydroxycycloartenoid
extracted from Combretum molle leaves have been investi-
gated in mice and rats [25]. The results of the laboratory
animal study indicate that MAG possesses analgesic and
anti-inflammatory effects in the mammalian models
used. The author suggested that MAG possesses both
centrally- and peripherally-mediated analgesic effects
[27]. In an investigation of the biological activity of dif-
ferent Combretum spp [16], C. molle was found to have
both anti-inflammatory and antischistosomal activity.
These findings may explain the traditional use of the
plant against malaria and pain. This study also contrib-
utes to the validation of the popular use of this plant
species in the treatment of inflammation.
H-PGDS is specific for and selectively and effectively
isomerizes PGH2 to PGD2, thus, efforts are being put into
searching for potential HPGDS inhibitors [5]. The activ-
ities of other GSTs have been reported to be inhibited by
S-hexyl glutathione (GSH) and its conjugation with 1-
Figure 4 Inhibition profile of C. molle alkaloids on GST Sigma. A shows the Michaelis-Menten plot and B the Lineweaver-Burk plot of GST
Sigma. In the assay GST Sigma activity was measured with varying concentrations of GSH and different inhibitor concentrations; 0, 2, 5, 10 and
20 μg/ml whilst GSH concentration was fixed at 5 mM.
Figure 5 Secondary plot to determine Ki for the alkaloids. Based
on the type of inhibition, a re-plot of 1/Vmax versus [I] was used to
determine Ki
GSH values of alkaloids, since an uncompetitive type
inhibition for GST Sigma with respect to GSH was obtained.
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investigation, C. molle alkaloids were tested for GST
inhibition in vitro. The effect of C. molle alkaloids on
H-PGDS was tested at 300 μg/ml concentration of the
plant extract. The inhibition profile was concentration-
dependent (Figure 4). Other data also showed concentration-
dependent inhibition of cytosolic GSTs when Mitragyna
speciosa extract was added into the reaction mixture [29].
In that study, the methanolic extract showed the highest
GSTs specific activity inhibition (61%), followed by aque-
ous (50%) and total alkaloid extract (43%), respectively
[29]. In this study, C. molle alkaloids reduced the enzyme
activity by 70%, thus, showing that the fractions were po-
tent inhibitors of H-PGDS. Compounds that inhibit GSTs
can prove to be potent drugs [30]. Since the whole leaf ex-
tract from C. molle was shown to be a potent inhibitor for
H-PGDS, further studies to determine the IC50 values for
alkaloids were carried out. C. molle alkaloid extract exhib-
ited inhibitory effects on H-PGDS with an IC50 of 13.7 μg/
ml. Since the IC50 value for the whole leaf extract was
found to be 16.7 μg/ml, it suggests that the inhibitory
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Figure 6 Secondary plots to determine Ki for the alkaloids for GST
Sigma with CDNB as the substrate. A Non-competitive inhibition was
obtained with respect to CDNB, and a re-plot of 1/Vmax versus [I] was
used to determine Ki
CDNB. In B, a replot of Km/Vmax versus [I] was used
to determine Ki′
CDNB for the alkaloids. The X- intercept as indicated by
the arrow gave the value -Ki which was used to calculate the Ki and K΄i
respectively. These gave values of Ki and Ki′ of 7.7 and 9.2 μg/ml.
Correlation coefficients of 0.84 and 0.99 were obtained for plots A and
B respectively.




(μg/ml) GSH CDNB GSH
0 171.2 ± 1.7 2366.8 ± 38.6 5.2 ± 0.04
2 162 ± 0.3 2281.3 ± 3.5 4.82 ± 0.12
5 149.5 ± 2.6 2218.6 ± 37.3 3.41 ± 0.007*
10 127.1 ± 5.3* 2118.4 ± 31.2 1.40 ± 0.02**
20 115.6 ± 1.9*** 2074.5 ± 3.2* 1.14 ± 0.06**
One-way analysis of variance test (ANOVA) with Dunnett’s Multiple Comparison Tes
The values with a p-value < 0.05 or less were considered statistically significant. *P <
out using Graphpad Prism 5® Software (Version 5.0, Graph pad Software Inc, San Di
Moyo et al. BMC Complementary and Alternative Medicine 2014, 14:221 Page 7 of 9
http://www.biomedcentral.com/1472-6882/14/221effects in the leaf extract were mainly due to the presence
of alkaloids in C. molle.
However, the IC50 value for the alkaloids was high as
compared to other GST inhibitors namely, hematin
(3.16 μg/ml), tributyltin bromide (2.2 μg/ml) and for S-
hexylglutathione (7.8 μg/ml) [31]. The difference can be
ascribed to the fact that this was a mixture and not pure
compounds. In a previous study [32], it was found that
the pure plant natural products ellagic acid and curcu-
min were potent inhibitors of GSTs with IC50 values of
0.6 and 0.9 μg/ml respectively and, therefore, purified
phytochemicals maybe be more effective than mixtures.
To determine if alkaloids from C. molle had other
modes of inhibition of H-PGDS, time-dependent incu-
bations of the alkaloids with the enzyme were carried
out. C. molle alkaloids failed to inactivate H-PGDS
(Figure 4). Activity at the beginning of the reaction was
concentration-dependent and lower than that of ciba-
cron blue at all concentrations. Thereafter, with pro-
gression in time, the activity remained constant showing
that the effects of the alkaloids were not time-dependent
but were reversible.
It was shown that the plant extract exhibited an uncom-
petitive type of inhibition with regards to GSH as both Km
and Vmax were decreasing and produced a Ki of 41 μg/ml.
Thus, the extract binds to the enzyme – substrate com-
plex only [33]. The inhibition was non-competitive with
respect to CDNB characterised by Ki value of 7.67 μg/ml
and Ki
′ of 9.18 μg/ml. This suggests that the extract binds
to the free enzyme and to the enzyme – substrate complex
[33]. In non-competitive inhibition, substrate can still bind
to the enzyme-inhibitor complex. However, the enzyme-
inhibitor-substrate complex does not proceed to form
product and the value of Vmax decreases to a new value
while the value of Km is unchanged [33]. In a previous
study, the Ki values for GSTs were 84.132 and 180 μg/ml
respectively for T. diversifolia, C. rotundus and H. sua-
volens extracts and, hence, C. molle alkaloid extract
with lower kinetic constants was a more potent GST
inhibitor [34].roperties of GST Sigma
Km(mM) Kcat/Km (S
−1 mM−1) Kcat/Km (S
−1 mM−1)
CDNB GSH CDNB
2.25 ± 0.04 33.17 ± 0.06 1051.2 ± 1.03
2.00 ± 0.02 33.62 ± 0,80 1136.14 ± 6.70
2.17 ± 0.007 43.82 ± 0.86 1020.19 ± 13.83
2.06 ± 0.02** 90.92 ± 4.81 1028.83 ± 5.96
2.02 ± 0.02** 101.9 ± 3.94 1029.36 ± 10.33
t was used to analyse the results. Values represent the mean ± SD for N = 2.
0.05, **P < 0.01 , ***P < 0.001. Graphical and Statistical analyses were carried
ego, USA).
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PGD2 in inflammation, the role of PGD2 in the host im-
mune response has been scantly studied [35]. Inflamma-
tion in H-PGDS knockout mice was found to be more
severe during the onset phase arising from a cytokine
imbalance which resulted in enhanced polymorpho-
nuclear leukocyte and monocyte trafficking [36]. Preven-
tion of H-PGDS activity specifically either through gene
knockout leads to impaired clearance of lymphocytes
and macrophages from sites of inflammation [36]. This
may be the case when H-PGDS is inhibited by C. molle
alkaloid extract. H-PGDS contributes to the production
of the D and J series of prostanoids in the immune sys-
tem and is involved in allergic inflammatory response.
Since H-PGDS is present in mast cells, Th2 cells, and
other leukocytes, it is thought to be mainly responsible
for PGD2 production during allergic responses. Inhib-
ition of H-PGDS will reduce the production of PGD2
and, hence, result in a decrease in allergies [35].
The substrate used in this study was CDNB which is
not the physiological substrate for H-PGDS. However,
C. molle alkaloid extract is more likely to possess anti-
H-PGDS activity even in the presence of PGH2 the
physiological substrate. The Km of H-PGDS obtained for
PGH2 was 0.2 mM [37] and in this study we obtained a
Km of 2.25 mM for CDNB. Although these values are
within a magnitude of difference, C. molle alkaloid extract
is still likely to have some inhibitory effects on H-PGDS in
the presence of PGH2. Further experiments using PGH2
as a substrate are needed to verify this claim.Conclusion
In conclusion, alkaloids from C. molle were shown to have
inhibitory effects on H-PGDS. The inhibitory effects were
lower as compared to cibacron blue, a standard H-PGDS
inhibitor. The alkaloids exhibited non-competitive and
un-competitive inhibition of H-PGDS with respect to
CDNB and GSH respectively. However, potent activity
in vitro cannot be directly correlated to potent activity
in vivo due to other factors such as metabolism within
cells and the presence of other compounds in the cell
which may prevent binding of the required compound to
its target site. The effect of C. molle alkaloid extract on H-
PGDS using PGH2 needs to be determined. This study
has, therefore, identified alkaloids from Combretum molle
with potential anti-inflammatory activity and may, therefore,
serve as sources of lead compounds for anti-inflammatory
drug development. The inhibitory effect of alkaloids from
C. molle also validates the use of its extracts in traditional
medicines to reduce inflammation.
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